Number of patients screened	7
Number of patients enrolled	6
Number of patients evaluable for toxicity	6
Number of patients evaluated for efficacy	6
Evaluation method	RECIST 1.1
Response assessment, CR	0(0%)
Response assessment, PR	0(0%)
Response assessment, SD	2(33.3%)
Response assessment, PD	4(66.7%)
(Median) Duration assessments, PFS	2.2 months; CI 2.1-13.7
(Median) Duration assessments, OS	NA; CI 5.8-NA